CTKB

Cytek Biosciences, Inc. (CTKB) | Rumor.io

Cytek Biosciences

CTKB

Attention (50-day avg)0%

Attention rank (50-day avg)#4,422

Bullish sentiment (50-day avg)100%

Price to earnings ratio374.5

Market capitalization746.1M

Earnings per share-0.63

Dividend yield (TTM)—

Revenue (annual)201.5M

Net income (annual)-66.5M

Social

What share of all stock conversation is about CTKB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Nov 17

$CTKB revenue is mentioned in passing, but the primary focus is on $NXXT's earnings and growth.
The posts primarily discuss $NXXT's strong earnings and revenue growth, with mentions of $CTKB in a secondary context.
There is no primary discussion of $CTKB's performance, and the posts focus on the implications of $NXXT's earnings for the broader market.

Generated by AI

Sentiment

Of the messages about CTKB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100%	95.35% +1.8
Bearish	0%	0%	0%	4.65% -1.8

Nov 17

$CTKB is breaking out with strong momentum, potentially reaching $6.
$NXXT's 232% YoY growth indicates explosive demand, and its margin expansion shows scaling is working.
$NXXT's revenue acceleration and strong sequential trend suggest accelerating fundamentals, with its market cap not yet reflecting this growth.

Generated by AI

Topics

Of the messages about CTKB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	100%	87.5%
Analysts	—	—	0%	2.5%
Announcements	—	—	0%	10%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%

Sep 2

Cytek Biosciences, Inc. ($CTKB) reports second quarter 2021 financial results.
The company will present at the Morgan Stanley 19th Annual Global Healthcare Conference.
$CTKB reports strong financial performance for Q2 2021, with results available via press release.

Generated by AI

Community

Of the messages about CTKB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	41.84%
Newcomers	100%	100%	100%	58.16%

Nov 17

Newcomers to the market are excited about the triple-digit fundamentals of NXXT, with a 232% YoY revenue increase and a 3.3× explosion in revenue growth compared to last year.
The company's operating leverage is showing early signs, with a 4× margin increase and a strong Q3 revenue print, setting up a potential 100-150% price jump on a single catalyst.
NXXT's growth numbers are stronger than many mid-cap clean-energy firms, with a YoY revenue outperformance that shows execution at full strength, and a market cap that doesn't yet reflect the accelerating fundamentals.

Generated by AI

News

Fund Divests Cytek Biosciences (CTKB) Following Revenue Slowdown and Declining Profitability

22h agoYahoo Finance

Cytek Biosciences launches cloud-based analysis tool

6d agoInvesting.com

Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?

Investors need to pay close attention to CTKB stock based on the movements in the options market lately.

12d agoYahoo Finance Singapore

Cytek at Morgan Stanley global healthcare conference: growth broadens

13d agoInvesting.com

Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry

Complementary Technologies Deliver an Integrated, End-to-End Clinical Flow Cytometry Workflow for Laboratories Across Europe Cytek Biosciences and Sysmex Europe Collaborate Cytek Biosciences and Sysmex Europe have signed an agreement establishing a strategic collaboration to enhance clinical flow cytometry workflows and expand access to innovative diagnostic solutions. By combining their complementary technologies, the collaboration will provide an integrated, end-to-end clinical flow cytometry

20d agoYahoo Finance

Cytek’s (CTKB) Instruments Keep Selling While Losses Keep Growing

On August 5, Cytek Biosciences (NASDAQ:CTKB) reported financial results for the second quarter ended June 30, and the report reads like two different companies at once. Revenue climbed, margins widened, and the installed base of instruments kept expanding. At the same time, the net loss more than doubled from a year earlier and adjusted EBITDA […]

21d agoYahoo Finance

Also Discussed

Investors talking about CTKB also mention

#	Name	Attention
1	GHLD - Guild Holdings Company	——
2	Sagimet Biosciences Inc. Series A Common StockSGMT	0%0
3	authID Inc.AUID	0%0
4	RAPT - RAPT Therapeutics, Inc.	——
5	Agape Atp CorpATPC	0%0
6	Indivior Pharmaceuticals, Inc.INDV	0%0
7	Moolec Science SAMLEC	0%new
8	Vertex Inc.VERX	0%new
9	GPGI IncCMPO	0%0
10	Belite Bio, Inc. ADRBLTE	0%new

Cytek Biosciences, Inc.

Healthcare
Medical Devices

Cytek Biosciences, Inc. is a cell analysis solutions company that develops and markets advanced flow cytometry systems, reagents, software, and services for biomedical research and clinical applications. The company’s portfolio centers on its Full Spectrum Profiling technology, which supports high-resolution, high-content, and high-sensitivity analysis of single cells. Its current product lineup includes the Aurora and Northern Lights cell analyzers, the Aurora CS cell sorter, and related integrated tools designed to help researchers study complex biological samples. Cytek Biosciences also offers conventional flow and image-based flow cytometry products through its acquired Amnis and Guava businesses, expanding its reach across cell analysis workflows. The company serves life science researchers and clinical laboratories with solutions used in areas such as immunology, cancer research, infectious disease, and inflammatory disease studies. Headquartered in Fremont, California, Cytek Biosciences focuses on providing a comprehensive platform for cell analysis in global research and applied science markets.

Website

Location

47215 Lakeview Boulevard

Fremont, CA, 94538

United States

Social

What share of all stock conversation is about CTKB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Nov 17

$CTKB revenue is mentioned in passing, but the primary focus is on $NXXT's earnings and growth.
The posts primarily discuss $NXXT's strong earnings and revenue growth, with mentions of $CTKB in a secondary context.
There is no primary discussion of $CTKB's performance, and the posts focus on the implications of $NXXT's earnings for the broader market.

Generated by AI

Sentiment

Of the messages about CTKB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100%	95.35% +1.8
Bearish	0%	0%	0%	4.65% -1.8

Nov 17

$CTKB is breaking out with strong momentum, potentially reaching $6.
$NXXT's 232% YoY growth indicates explosive demand, and its margin expansion shows scaling is working.
$NXXT's revenue acceleration and strong sequential trend suggest accelerating fundamentals, with its market cap not yet reflecting this growth.

Generated by AI

Topics

Of the messages about CTKB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	100%	87.5%
Analysts	—	—	0%	2.5%
Announcements	—	—	0%	10%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%

Sep 2

Cytek Biosciences, Inc. ($CTKB) reports second quarter 2021 financial results.
The company will present at the Morgan Stanley 19th Annual Global Healthcare Conference.
$CTKB reports strong financial performance for Q2 2021, with results available via press release.

Generated by AI

Community

Of the messages about CTKB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	41.84%
Newcomers	100%	100%	100%	58.16%

Nov 17

Newcomers to the market are excited about the triple-digit fundamentals of NXXT, with a 232% YoY revenue increase and a 3.3× explosion in revenue growth compared to last year.
The company's operating leverage is showing early signs, with a 4× margin increase and a strong Q3 revenue print, setting up a potential 100-150% price jump on a single catalyst.
NXXT's growth numbers are stronger than many mid-cap clean-energy firms, with a YoY revenue outperformance that shows execution at full strength, and a market cap that doesn't yet reflect the accelerating fundamentals.

Generated by AI

Cytek Biosciences

Social

Nov 17

Nov 17

Sep 2

Nov 17

Fund Divests Cytek Biosciences (CTKB) Following Revenue Slowdown and Declining Profitability

Cytek Biosciences launches cloud-based analysis tool

Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?

Cytek at Morgan Stanley global healthcare conference: growth broadens

Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry

Cytek’s (CTKB) Instruments Keep Selling While Losses Keep Growing

Also Discussed

Cytek Biosciences, Inc.

Company Information

Location

Fund Divests Cytek Biosciences (CTKB) Following Revenue Slowdown and Declining Profitability

Cytek Biosciences launches cloud-based analysis tool

Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?

Cytek at Morgan Stanley global healthcare conference: growth broadens

Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry

Cytek’s (CTKB) Instruments Keep Selling While Losses Keep Growing

Also Discussed

Social

Nov 17

Nov 17

Sep 2

Nov 17